Home » Healthcare » Oncology Molecular Diagnostics Market

Oncology Molecular Diagnostics Market By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, Others) By Product (Instruments, Reagents, Others) -Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Price: $4999

Published: | Report ID: 20247 | Report Format : PDF

Actionable Insights Delivered – Oncology Molecular Diagnostics Market Size

Positioned with a USD 4.5 Billion valuation in 2022, the Oncology Molecular Diagnostics Market asserted its global eminence. Set to scale to USD 12.3 Billion by 2030, the market’s remarkable Compound Annual Growth Rate (CAGR) of 15.5% (2022-2030) underscores its strategic growth trajectory.

Key Highlights of the Report

The global oncology molecular diagnostics market is segmented by type, product, test location, technology, end user, and region. Lung cancer is the most widely used, while reagents are a widely utilized segment. Clinics are the most used, while PCR is a widely utilized segment. North America is leading the market growth.

The growing frequency of cancer, which calls for better diagnostic methods for early identification and monitoring, and developments in precision medicine, which enable tailored treatment approaches based on genomic profiles, are two factors driving the oncology molecular diagnostics market. The high cost of molecular diagnostics is one barrier to the industry, limiting accessibility and acceptance in specific healthcare settings and geographical areas.

Nonetheless, the global oncology molecular diagnostics market are the combination of artificial intelligence (AI) and machine learning (ML) algorithms to improve the precision and effectiveness of data analysis, interpretation, and decision-making, as well as the potential for liquid biopsy technologies to revolutionize cancer diagnostics by enabling non-invasive detection and monitoring of tumor-related genetic alterations in circulating biomarkers like ctDNA (circulating DNA), are two opportunities for the oncology molecular diagnostics market.

What Are The Main Drivers Of The Global Oncology Molecular Diagnostics Market?

The global increase in cancer incidence is a significant market driver for oncology molecular diagnostics. Given the rising incidence of cancer incidence, early detection, precise diagnosis, and efficient treatment planning, improved diagnostic technologies and techniques are required.

What Are The Major Challenges Faced By The Global Oncology Molecular Diagnostics Market?

The high cost of molecular diagnostic tests and technology makes it difficult for these diagnostics to be widely used and accessible, especially in settings with low resources. The cost of the necessary tools, chemicals, and qualified personnel for molecular diagnostics can make them difficult.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

What Are The Growth Opportunities In The Global Oncology Molecular Diagnostics Market?

The possibility of developing tailored medicines is made possible by our growing understanding of cancer’s molecular and genetic underpinnings. Specific biomarkers and genetic alterations can be found using oncology molecular diagnostics, allowing for selecting individualized therapy choices and improving patient outcomes.

Executive Summary

Overview of the Global Oncology Molecular Diagnostics Market

The rising incidence of cancer and the demand for precise and early detection are major growth drivers for the global market for oncology molecular diagnostics. The market is growing due to developments in precision medicine and the application of genomics in clinical settings. Creating cutting-edge technologies like liquid biopsies and applying AI and ML to data analysis distinguishes the market. But there are also issues like high costs, complicated regulations, and the requirement for consistent interpretation of results. Overall, because of developments in cancer genetics and molecular biology, the market offers growth possibilities in personalized medicine, targeted therapies, and non-invasive diagnostics.

Market Definition

Oncology molecular diagnostics encompass a variety of examinations and methods used to examine the genetic and molecular changes connected to cancer. These diagnostics locate particular biomarkers, gene mutations, and other molecular anomalies indicative of various cancer forms. They are extremely important in the detection, diagnosis, prognosis, choice of treatment, and follow-up of cancer patients. The genetic material, proteins, and other molecular components of tumor cells are analyzed by oncology molecular diagnostics using various technologies, including polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization, mass spectrometry, and microarrays. These tests contribute to developing precision medicine in oncology, providing individualized and focused treatment options, and improving patient outcomes.

Oncology Molecular Diagnostics Market

Market Insights

  • The global demand for oncology molecular diagnostics was valued at USD 4.5 Billion in 2022 and is expected to reach USD 12.3 Billion in 2030, growing at a CAGR of 15.5% between 2023 and 2030.
  • Lung cancer is the market leader in the type and will hold over 20% of the market’s value in 2022, while blood cancer is anticipated to show the quickest CAGR over the forecast period.
  • The reagents segment governs the global demand for oncology molecular diagnostics, holding a massive share of over 30% in 2022, and is expected to grow at a rapid CAGR.
  • Clinics are the market leader in test location, holding over 40% of the market’s value in 2022.
  • The PCR (Polymerase Chain Reaction) segment governs the global demand for oncology molecular diagnostics, holding a massive share of over 12% in 2022, and is expected to grow at a rapid CAGR.
  • Hospitals are the market leader in the type and hold over 70% of the market’s value in 2022, while Diagnostic centers are anticipated to show the quickest CAGR over the forecast period,
  • North America is fueling the growth of the oncology molecular diagnostics industry with over one-third share in 2022. Europe and Asia Pacific collectively accounted for just under 40% share in 2022. Asia Pacific held over 22% share in 2022.
  • Due to its sophisticated healthcare infrastructure, robust research and development efforts, and high adoption of molecular diagnostic technologies in cancer management, the North American region is leading the oncology molecular diagnostics market.
  • The growing desire for targeted medicines and customized medicine, which depend on precise genetic profiling and molecular testing to inform treatment decisions, is one factor driving the oncology molecular diagnostics market. However, the complicated regulatory environment and the requirement for rigorous validation and regulatory approvals are market restraints that can delay the commercialization of innovative molecular diagnostic tests and technologies.

Segmentation by Type

  • Lung cancer is the leading segment by type and will hold over 20% share in value in 2022.
  • Blood cancer will likely exhibit the fastest CAGR during the forecast period.

Segmentation by Product

  • The reagents segment governs the global demand for oncology molecular diagnostics, holding a massive share of over 30% in 2022, and is also expected to grow at a rapid CAGR.
  • Instruments contribute to the rest of the demand for oncology molecular diagnostics.

Segmentation by Test location

  • Clinics are the leading segment by type, holding over 40% share in value in 2022.
  • The point of care industry segment will likely exhibit the fastest CAGR during the forecast period.

Segmentation by Technology

  • PCR (Polymerase Chain Reaction) is the leading segment by type, holding over 12% share in value in 2022.
  • The mass spectrometry segment will likely exhibit the fastest CAGR during the forecast period.

Segmentation by End User

  • The hospitals segment governs the global demand for oncology molecular diagnostics, holding a massive share of over 70% in 2022, and is also expected to grow at a rapid CAGR.
  • The diagnostic centers segment contributes to the rest of the demand for oncology molecular diagnostics.

Segmentation by Region

  • North America is fueling the growth of the oncology molecular diagnostics industry with over one-third share in 2022.
  • Asia Pacific and Europe collectively account for just under 40% share in 2022, with Asia Pacific holding over 22% share in the same year.
  • The rest of the World, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for oncology molecular diagnostics.

The increased focus on early cancer identification and prevention, motivated by the understanding that early intervention can greatly improve patient outcomes, drives the oncology molecular diagnostics industry. As a result, there is now more demand for molecular diagnostic tests that may accurately identify cancer in its early stages, allowing for prompt treatment and intervention.

The oncology molecular diagnostics market is heavily used in the US to assist cutting-edge cancer treatment. Molecular diagnostics are crucial in cancer management due to their excellent research skills and well-developed healthcare infrastructure. They are employed for precise diagnosis, prognosis, and therapy decision-making. Identifying specific biomarkers and gene mutations made possible by genetic profiling through molecular diagnostics helps inform targeted medicines and personalized medicine methods. Additionally, liquid biopsy technologies are used more frequently to detect minimal residual disease and non-invasively evaluate treatment response. Collaborations between academia, business, and healthcare providers drive innovation and the market’s uptake of cutting-edge molecular diagnostic technology.

The oncology molecular diagnostics market has grown tremendously in China in recent years. The extensive use of molecular diagnostic tests results from increased cancer incidence and the growing public understanding of personalized therapy. These tests support the early identification and precise diagnosis of different cancer forms, facilitating prompt treatment and better patient outcomes. Furthermore, molecular diagnostics are essential for directing targeted medicines, tracking treatment efficacy, and detecting minimum residual disease. The market in China benefits from the nation’s substantial population, sophisticated healthcare system, and government initiatives to advance cancer treatment and promote precision medicine. The development and implementation of molecular diagnostic technologies in the Chinese market are facilitated by cooperation between business stakeholders, academic institutions, and healthcare providers.:

Increasing Emphasis On Personalized Medicine

The growing emphasis on personalized medicine and targeted medicines is one major factor driving the market for oncology molecular diagnostics. The demand for molecular diagnostics has increased due to the realization that each person’s cancer is distinct at the molecular level. These diagnostics make it possible to pinpoint specific genetic changes, biomarkers, and molecular fingerprints linked to certain cancer types.

Clinicians can customize treatment strategies to the unique features of each patient’s cancer by evaluating the genomic profile of tumors, leading to more effective and accurate therapy. Based on a patient’s molecular profile, matching patients with the most effective targeted medicines is possible, potentially improving treatment success and lowering side effects.

Development Of Genomic Technology And Research

The development of genomic technology and research is a significant additional factor driving the oncology molecular diagnostics industry. The capabilities of molecular diagnostics in oncology have increased due to the quick advancements in genomics, next-generation sequencing (NGS), and other molecular techniques.

Comprehensive genomic profiling of tumors is now possible due to the falling costs and rising accessibility of sequencing technology, allowing for a deeper comprehension of the molecular causes of cancer. As a result, new biomarkers and genetic abnormalities linked to various cancer kinds have been found, allowing for more accurate diagnosis, prognosis, and therapy choice.

Additionally, the introduction of liquid biopsy methods, which enable the identification of genetic material from tumors in bodily fluids, has transformed cancer diagnostics by offering a non-invasive way to track the development of the condition and the effectiveness of treatment in real-time. The scope and effect of molecular diagnostics in the field of oncology have greatly increased as a result of these technological and genomic developments.

Complicated Regulatory Environment

The complicated regulatory environment and requirement for exacting validation and regulatory approvals is a major limitation on the market for oncology molecular diagnostics. To assure accuracy, dependability, and clinical utility, rigorous validation techniques must be applied to molecular diagnostic tests and technologies. It can take a lot of time and money to obtain regulatory approvals from health authorities like the FDA in the US or the European Medicines Agency (EMA) in Europe.

Distinct regions have distinct regulatory needs, making it difficult for market participants to navigate the regulatory environment and adhere to the relevant standards. It’s also possible that different healthcare systems’ reimbursement procedures and insurance coverage for molecular diagnostic tests will impact how widely used and accessible these tests are.

Growing Demand for Sustainable Agriculture Solutions

Combining artificial intelligence (AI) and machine learning (ML) algorithms represents a huge commercial opportunity in oncology molecular diagnostics. The accuracy, effectiveness, and interpretation of molecular diagnostic data could be improved using AI and ML.

These tools can help to extract patterns, make predictions, and offer insights from enormous amounts of genetic data. AI-powered algorithms can enhance clinical decision-making and treatment planning by assisting with data analysis, variant calling, and interpretation of complex genetic variations. It is possible to increase diagnostic precision, decrease turnaround times, and increase testing efficiency by incorporating AI and ML into molecular diagnostics.

Advancements in Precision Breeding Techniques

The development and uptake of liquid biopsy technology represent another important business potential in oncology molecular diagnostics. Liquid biopsy examines tumor-derived genetic material in bodily fluids like blood or urine, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes.

This non-invasive method provides several benefits, such as the capacity to identify the establishment of resistance mutations, monitor disease progression, evaluate therapy response, and discover genetic modifications without the need for invasive tissue samples. Liquid biopsy has the potential to enable real-time monitoring, long-term evaluation, and early cancer recurrence identification.

It also makes it possible to determine minimal residual disease and measure tumor heterogeneity. If widely used, liquid biopsy methods can change cancer diagnosis by enabling individualized and dynamic tumor monitoring, assisting with therapy selection, and enhancing patient outcomes. The future of molecular diagnostics in oncology is extremely promising due to ongoing research and development.

Competitive Landscape

Key Players

The global oncology molecular diagnostics market is highly competitive, with several key players. Some of the major players in the market and their market share are as follows:

  • Abbott
  • Bayer AG
  • BD
  • Agilent Technologies, Inc
  • Danaher
  • Hologic, Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare Private Limited
  • Sysmex Singapore Pte. Ltd.
  • BIOMÉRIEUX
  • DiaSorin Molecular LLC
  • Grifols, S.A.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmbH
  • Analytik Jena GmbH
  • Biocartis
  • GenMark Diagnostics, Inc
  • HTG Molecular Diagnostics, Inc.

A wide variety of businesses are operating in the oncology molecular diagnostics market, including huge multinational enterprises, mid-sized businesses, and rising startups. The competition between the market’s major competitors is built on the creation of novel technologies, clever alliances, product launches, and market expansion plans to acquire an advantage and increase market share.

The Precision Oncology Patient Identification Program for thyroid cancer will proceed thanks to a partnership between Veracyte Inc. and Bayer AG in December 2020. For patients with advanced thyroid cancer to benefit from biomarker-driven therapy, the research is anticipated to enable testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genetic drivers in tumor cells.

In February 2020, Danaher (Cepheid) and Sherlock Biosciences established a partnership to investigate the development of novel, ground-breaking molecular diagnostic assays for infectious illnesses and oncology using CRISPR technology.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Summary of Key Findings

  • Blood cancer is predicted to see the fastest CAGR during the forecast period, while lung cancer is the market leader of the kind and will hold more than 20% of the market’s value in 2022.
  • The reagents sector predicted to develop at a high CAGR, will dominate the global market for oncology molecular diagnostics in 2022, accounting for a sizable proportion of over 30%.
  • With more than 40% of the market’s value held by clinics in 2022, they are the market leader in test locations.
  • The PCR (Polymerase Chain Reaction) category, predicted to develop at a high CAGR, now controls the global demand for oncology molecular diagnostics. Its share will be over 12% in 2022.
  • Hospitals are the category leader and will account for more than 70% of market revenue in 2022; however, diagnostic centers are expected to grow faster.
  • North America will account for approximately one-third of the global demand for oncology molecular diagnostics 2022. Europe and Asia-Pacific made for just under 40% of the market in 2022. In 2022, Asia Pacific owned a share of over 22%.

Future Outlook

  • Advancements in genetics, technology, and data analysis methods drive the development of increasingly precise and thorough molecular diagnostic procedures.
  • Molecular diagnostics will be essential in directing targeted therapies and enhancing patient outcomes due to the growing emphasis on precision medicine and tailored treatment methods.
  • The effectiveness and precision of data analysis will be further improved by incorporating artificial intelligence and machine learning techniques.
  • Furthermore, the ongoing study and development of liquid biopsy technologies are promising for non-invasive monitoring and early cancer identification, opening the door for revolutionary improvements in cancer diagnostics.

Segmentation

  • By Type
    • Breast Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Liver Cancer
    • Lung Cancer
    • Blood Cancer
    • Kidney Cancer
    • Others
  • By Product
    • Instruments
    • Reagents
    • Others
  • By Test location
    • Clinics
    • Other Establishments
    • Point of Care
  • By Technology
    • PCR
    • Multiplex
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
  • By End User
    • Hospitals
    • Diagnostic Centers
  • By Region
  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Oncology Molecular Diagnostics Market
2.2. Global Oncology Molecular Diagnostics Market, By Type
2.3. Global Oncology Molecular Diagnostics Market, By Product
2.4. Global Oncology Molecular Diagnostics Market, By Test Location
2.5. Global Oncology Molecular Diagnostics Market, By Technology
2.6. Global Oncology Molecular Diagnostics Market, By End User
2.7. Global Oncology Molecular Diagnostics Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Oncology Molecular Diagnostics Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Driver 1
3.2.1.2. Driver 2
3.2.1.3. Driver 3
3.2.2. Market Restraints
3.2.2.1. Restraint 1
3.2.2.2. Restraint 2
3.2.3. Market Opportunities
3.2.3.1. Opportunity 1
3.2.3.2. Opportunity 2
3.2.4. Major Industry Challenges
3.2.4.1. Challenge 1
3.2.4.2. Challenge 2
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type
3.5.2. Product
3.5.3. Test Location
3.5.4. Technology
3.5.5. End User
3.5.6. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Test Location
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Type Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. InDirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Oncology Molecular Diagnostics Market, By Type
7.1. Global Oncology Molecular Diagnostics Market Overview, by Type
7.1.1. Global Oncology Molecular Diagnostics Market Revenue Share, By Type, 2022 Vs 2030 (in %)
7.2. Breast Cancer
7.2.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
7.3. Prostate Cancer
7.3.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
7.4. Colorectal Cancer
7.4.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
7.5. Cervical Cancer
7.5.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
7.6. Liver Cancer
7.6.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
7.7. Lung Cancer
7.7.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
7.8. Blood Cancer
7.8.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
7.9. Kidney Cancer
7.9.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
7.10. Others
7.10.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)

8. Global Oncology Molecular Diagnostics Market, By Product
8.1. Global Oncology Molecular Diagnostics Market Overview, by Product
8.1.1. Global Oncology Molecular Diagnostics Market, By Product, 2022 vs 2030 (in %)
8.2. Instruments
8.2.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
8.3. Reagents
8.3.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
8.4. Others
8.4.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)

9. Global Oncology Molecular Diagnostics Market, by Test Location, 2017-2030 (US$ Bn)
9.1. Global Oncology Molecular Diagnostics Market Overview, by Test Location
9.1.1. Global Oncology Molecular Diagnostics Market, By Test Location, 2022 vs 2030 (in%)
9.2. Clinics
9.2.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
9.3. Other Establishments
9.3.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
9.4. Point of Care
9.4.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)

10. Global Oncology Molecular Diagnostics Market, by Technology, 2017-2030 (US$ Bn)
10.1. Global Oncology Molecular Diagnostics Market Overview, by Technology
10.1.1. Global Oncology Molecular Diagnostics Market, By Test Location, 2022 vs 2030 (in%)
10.2. PCR
10.2.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
10.3. Multiplex
10.3.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
10.4. In Situ Hybridization
10.4.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
10.5. Isothermal Nucleic Acid Amplification Technology (INAAT)
10.5.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
10.6. Chips and Microarrays
10.6.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
10.7. Mass Spectrometry
10.7.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
10.8. Sequencing
10.8.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
10.9. Transcription Mediated Amplification
10.9.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
10.10. Others
10.10.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)

11. Global Oncology Molecular Diagnostics Market, by Test Location, 2017-2030 (US$ Bn)
11.1. Global Oncology Molecular Diagnostics Market Overview, by End User
11.1.1. Global Oncology Molecular Diagnostics Market, By End User, 2022 vs 2030 (in%)
11.2. Hospitals
11.2.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)
11.3. Diagnostic Centers
11.3.1. Global Oncology Molecular Diagnostics Market, By Region, 2017-2030 (US$ Bn)

12. Global Oncology Molecular Diagnostics Market, By Region
12.1. Global Oncology Molecular Diagnostics Market Overview, by Region
12.1.1. Global Oncology Molecular Diagnostics Market, By Region, 2022 vs 2030 (in%)
12.2. Type
12.2.1. Global Oncology Molecular Diagnostics Market, By Type, 2017-2030 (US$ Bn)
12.3. Product
12.3.1. Global Oncology Molecular Diagnostics Market, By Product, 2017-2030 (US$ Bn)
12.4. Test Location
12.4.1. Global Oncology Molecular Diagnostics Market, By Test Location, 2017-2030 (US$ Bn)
12.5. Technology
12.5.1. Global Oncology Molecular Diagnostics Market, By Technology, 2017-2030 (US$ Bn)
12.6. End User
12.6.1. Global Oncology Molecular Diagnostics Market, By End User, 2017-2030 (US$ Bn)

13. North America Oncology Molecular Diagnostics Market Analysis
13.1. North America Oncology Molecular Diagnostics Market, by Type, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. North America Oncology Molecular Diagnostics Market, by Product, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. North America Oncology Molecular Diagnostics Market, by Test Location, 2017-2030(US$ Bn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. North America Oncology Molecular Diagnostics Market, by Technology, 2017-2030(US$ Bn)
13.4.1. Overview
13.4.2. SRC Analysis
13.5. North America Oncology Molecular Diagnostics Market, by End User, 2017-2030(US$ Bn)
13.5.1. Overview
13.5.2. SRC Analysis
13.6. North America Oncology Molecular Diagnostics Market, by Country, 2017-2030 (US$ Bn)
13.6.1. North America Oncology Molecular Diagnostics Market, by Country, 2022 Vs 2030 (in%)
13.6.2. U.S.
13.6.2.1. U.S. Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.6.2.2. U.S. Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
13.6.2.3. U.S. Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
13.6.2.4. U.S. Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
13.6.2.5. U.S. Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
13.6.2.6. U.S. Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
13.6.3. Canada
13.6.3.1. Canada Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.6.3.2. Canada Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
13.6.3.3. Canada Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
13.6.3.4. Canada Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
13.6.3.5. Canada Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
13.6.3.6. Canada Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
13.6.4. Mexico
13.6.4.1. Mexico Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.6.4.2. Mexico Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
13.6.4.3. Mexico Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
13.6.4.4. Mexico Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
13.6.4.5. Mexico Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
13.6.4.6. Mexico Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)

14. Europe Oncology Molecular Diagnostics Market Analysis
14.1. Europe Oncology Molecular Diagnostics Market, by Type, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Europe Oncology Molecular Diagnostics Market, by Product, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Europe Oncology Molecular Diagnostics Market, by Test Location, 2017-2030(US$ Bn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Europe Oncology Molecular Diagnostics Market, by Technology, 2017-2030(US$ Bn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. Europe Oncology Molecular Diagnostics Market, by End User, 2017-2030(US$ Bn)
14.5.1. Overview
14.5.2. SRC Analysis
14.6. Europe Oncology Molecular Diagnostics Market, by Country, 2017-2030 (US$ Bn)
14.6.1. Europe Oncology Molecular Diagnostics Market, by Country, 2022 Vs 2030 (in%)
14.6.2. Germany
14.6.2.1. Germany Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.6.2.2. Germany Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
14.6.2.3. Germany Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
14.6.2.4. Germany Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
14.6.2.5. Germany Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
14.6.2.6. Germany Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
14.6.3. France
14.6.3.1. France Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.6.3.2. France Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
14.6.3.3. France Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
14.6.3.4. Germany Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
14.6.3.5. Germany Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
14.6.3.6. Germany Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
14.6.4. UK
14.6.4.1. UK Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.6.4.2. UK Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
14.6.4.3. UK Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
14.6.4.4. UK Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
14.6.4.5. UK Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
14.6.4.6. UK Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
14.6.5. Italy
14.6.5.1. Italy Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.6.5.2. Italy Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
14.6.5.3. Italy Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
14.6.5.4. Italy Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
14.6.5.5. Italy Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
14.6.5.6. Italy Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
14.6.6. Spain
14.6.6.1. Spain Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.6.6.2. Spain Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
14.6.6.3. Spain Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
14.6.6.4. Spain Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
14.6.6.5. Spain Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
14.6.6.6. Spain Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
14.6.7. Rest of Europe
14.6.7.1. Rest of Europe Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.6.7.2. Rest of Europe Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
14.6.7.3. Rest of Europe Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
14.6.7.4. Rest of Europe Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
14.6.7.5. Rest of Europe Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
14.6.7.6. Rest of Europe Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)

15. Asia Pacific Oncology Molecular Diagnostics Market Analysis
15.1. Asia Pacific Oncology Molecular Diagnostics Market, by Type, 2017-2030(US$ Bn)
15.1.1. Overview
15.1.2. SRC Analysis
15.2. Asia Pacific Oncology Molecular Diagnostics Market, by Product, 2017-2030(US$ Bn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Asia Pacific Oncology Molecular Diagnostics Market, by Test Location, 2017-2030(US$ Bn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Asia Pacific Oncology Molecular Diagnostics Market, by Technology, 2017-2030(US$ Bn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Asia Pacific Oncology Molecular Diagnostics Market, by End User, 2017-2030(US$ Bn)
15.5.1. Overview
15.5.2. SRC Analysis
15.6. Asia Pacific Oncology Molecular Diagnostics Market, by Country, 2017-2030 (US$ Bn)
15.6.1. Asia Pacific Oncology Molecular Diagnostics Market, by Country, 2022 Vs 2030 (in%)
15.6.2. China
15.6.2.1. China Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.6.2.2. China Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
15.6.2.3. China Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
15.6.2.4. China Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
15.6.2.5. China Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
15.6.2.6. China Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
15.6.3. Japan
15.6.3.1. Japan Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.6.3.2. Japan Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
15.6.3.3. Japan Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
15.6.3.4. Japan Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
15.6.3.5. Japan Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
15.6.3.6. Japan Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
15.6.4. India
15.6.4.1. India Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.6.4.2. India Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
15.6.4.3. India Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
15.6.4.4. India Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
15.6.4.5. India Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
15.6.4.6. India Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
15.6.5. South Korea
15.6.5.1. South Korea Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.6.5.2. South Korea Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
15.6.5.3. South Korea Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
15.6.5.4. South Korea Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
15.6.5.5. South Korea Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
15.6.5.6. South Korea Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
15.6.6. South-East Asia
15.6.6.1. South-East Asia Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.6.6.2. South-East Asia Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
15.6.6.3. South-East Asia Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
15.6.6.4. South-East Asia Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
15.6.6.5. South-East Asia Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
15.6.6.6. South-East Asia Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
15.6.7. Rest of Asia Pacific
15.6.7.1. Rest of Asia Pacific Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.6.7.2. Rest of Asia Pacific Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
15.6.7.3. Rest of Asia Pacific Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
15.6.7.4. Rest of Asia Pacific Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
15.6.7.5. Rest of Asia Pacific Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
15.6.7.6. Rest of Asia Pacific Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)

16. Latin America Oncology Molecular Diagnostics Market Analysis
16.1. Latin America Oncology Molecular Diagnostics Market, by Type, 2017-2030(US$ Bn)
16.1.1. Overview
16.1.2. SRC Analysis
16.2. Latin America Oncology Molecular Diagnostics Market, by Product, 2017-2030(US$ Bn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Latin America Oncology Molecular Diagnostics Market, by Test Location, 2017-2030(US$ Bn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Latin America Oncology Molecular Diagnostics Market, by Technology, 2017-2030(US$ Bn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Latin America Oncology Molecular Diagnostics Market, by End User, 2017-2030(US$ Bn)
16.5.1. Overview
16.5.2. SRC Analysis
16.6. Latin America Oncology Molecular Diagnostics Market, by Country, 2017-2030 (US$ Bn)
16.6.1. Latin America Oncology Molecular Diagnostics Market, by Country, 2022 Vs 2030 (in%)
16.6.2. Brazil
16.6.2.1. Brazil Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
16.6.2.2. Brazil Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
16.6.2.3. Brazil Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
16.6.2.4. Brazil Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
16.6.2.5. Brazil Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
16.6.2.6. Brazil Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
16.6.3. Argentina
16.6.3.1. Argentina Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
16.6.3.2. Argentina Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
16.6.3.3. Argentina Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
16.6.3.4. Argentina Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
16.6.3.5. Argentina Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
16.6.3.6. Argentina Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
16.6.4. Rest of Latin America
16.6.4.1. Rest of Latin America Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
16.6.4.2. Rest of Latin America Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
16.6.4.3. Rest of Latin America Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
16.6.4.4. Rest of Latin America Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
16.6.4.5. Rest of Latin America Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
16.6.4.6. Rest of Latin America Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)

17. Middle East and Africa Oncology Molecular Diagnostics Market Analysis
17.1. Middle East and Africa Oncology Molecular Diagnostics Market, by Type, 2017-2030(US$ Bn)
17.1.1. Overview
17.1.2. SRC Analysis
17.2. Middle East and Africa Oncology Molecular Diagnostics Market, by Product, 2017-2030(US$ Bn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Middle East and Africa Oncology Molecular Diagnostics Market, by Test Location, 2017-2030(US$ Bn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Middle East and Africa Oncology Molecular Diagnostics Market, by Technology, 2017-2030(US$ Bn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Middle East and Africa Oncology Molecular Diagnostics Market, by End User, 2017-2030(US$ Bn)
17.5.1. Overview
17.5.2. SRC Analysis
17.6. Middle East and Africa Oncology Molecular Diagnostics Market, by Country, 2017-2030 (US$ Bn)
17.6.1. Middle East and Africa Oncology Molecular Diagnostics Market, by Country, 2022 Vs 2030 (in%)
17.6.2. GCC Countries
17.6.2.1. GCC Countries Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
17.6.2.2. GCC Countries Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
17.6.2.3. GCC Countries Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
17.6.2.4. GCC Countries Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
17.6.2.5. GCC Countries Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
17.6.2.6. GCC Countries Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
17.6.3. South Africa
17.6.3.1. South Africa Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
17.6.3.2. South Africa Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
17.6.3.3. South Africa Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
17.6.3.4. South Africa Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
17.6.3.5. South Africa Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
17.6.3.6. South Africa Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)
17.6.4. Rest of Middle East and Africa
17.6.4.1. Rest of Middle East and Africa Oncology Molecular Diagnostics Market Estimates and Forecast, 2017-2030 (US$ Bn)
17.6.4.2. Rest of Middle East and Africa Oncology Molecular Diagnostics, By Type, 2017-2030 (US$ Bn)
17.6.4.3. Rest of Middle East and Africa Oncology Molecular Diagnostics, By Product, 2017-2030 (US$ Bn)
17.6.4.4. Rest of Middle East and Africa Oncology Molecular Diagnostics, By Test Location, 2017-2030 (US$ Bn)
17.6.4.5. Rest of Middle East and Africa Oncology Molecular Diagnostics, By Technology, 2017-2030 (US$ Bn)
17.6.4.6. Rest of Middle East and Africa Oncology Molecular Diagnostics, By End User, 2017-2030 (US$ Bn)

18. Company Profiles
18.1. Abbott
18.1.1. Company Overview
18.1.2. Products/Products Portfolio
18.1.3. Geographical Presence
18.1.4. Financial Summary
18.1.4.1. Market Revenue and Net Profit (2019-2022)
18.1.4.2. Business Segment Revenue Analysis
18.1.4.3. Geographical Revenue Analysis
18.2. Bayer AG
18.3. BD
18.4. Agilent Technologies, Inc
18.5. Danaher
18.6. Hologic, Inc.
18.7. QIAGEN
18.8. F. Hoffmann-La Roche Ltd
18.9. Siemens Healthcare Private Limited
18.10. Sysmex Singapore Pte. Ltd.
18.11. BIOMÉRIEUX
18.12. DiaSorin Molecular LLC
18.13. Grifols, S.A.
18.14. Illumina, Inc.
18.15. Thermo Fisher Scientific Inc.
18.16. Leica Biosystems Nussloch GmbH
18.17. Analytik Jena GmbH
18.18. Biocartis
18.19. GenMark Diagnostics, Inc
18.20. HTG Molecular Diagnostics, Inc.

List of Figures
FIG. 1 Global Oncology Molecular Diagnostics Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Oncology Molecular Diagnostics Market Segmentation
FIG. 4 Global Oncology Molecular Diagnostics Market, by Type, 2022 (US$ Bn)
FIG. 5 Global Oncology Molecular Diagnostics Market, by Product, 2022 (US$ Bn)
FIG. 6 Global Oncology Molecular Diagnostics Market, by Test Location, 2022 (US$ Bn)
FIG. 7 Global Oncology Molecular Diagnostics Market, by Technology, 2022 (US$ Bn)
FIG. 8 Global Oncology Molecular Diagnostics Market, by End User, 2022 (US$ Bn)
FIG. 9 Global Oncology Molecular Diagnostics Market, by Geography, 2022 (US$ Bn)
FIG. 10 Attractive Investment Proposition, by Type, 2022
FIG. 11 Attractive Investment Proposition, by Product, 2022
FIG. 12 Attractive Investment Proposition, by Test Location, 2022
FIG. 13 Attractive Investment Proposition, by Technology, 2022
FIG. 14 Attractive Investment Proposition, by End User, 2022
FIG. 15 Attractive Investment Proposition, by Geography, 2022
FIG. 16 Global Market Share Analysis of Key Oncology Molecular Diagnostics Market Manufacturers, 2022
FIG. 17 Global Market Positioning of Key Oncology Molecular Diagnostics Market Manufacturers, 2022
FIG. 18 Global Oncology Molecular Diagnostics Market Value Contribution, By Type, 2022 & 2030 (Value %)
FIG. 19 Global Oncology Molecular Diagnostics Market, by Breast Cancer, Value, 2017-2030 (US$ Bn)
FIG. 20 Global Oncology Molecular Diagnostics Market, by Prostate Cancer, Value, 2017-2030 (US$ Bn)
FIG. 21 Global Oncology Molecular Diagnostics Market, by Colorectal Cancer, Value, 2017-2030 (US$ Bn)
FIG. 22 Global Oncology Molecular Diagnostics Market, by Cervical Cancer, Value, 2017-2030 (US$ Bn)
FIG. 23 Global Oncology Molecular Diagnostics Market, by Liver Cancer, Value, 2017-2030 (US$ Bn)
FIG. 24 Global Oncology Molecular Diagnostics Market, by Lung Cancer, Value, 2017-2030 (US$ Bn)
FIG. 25 Global Oncology Molecular Diagnostics Market, by Blood Cancer, Value, 2017-2030 (US$ Bn)
FIG. 26 Global Oncology Molecular Diagnostics Market, by Kidney Cancer, Value, 2017-2030 (US$ Bn)
FIG. 27 Global Oncology Molecular Diagnostics Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 28 Global Oncology Molecular Diagnostics Market Value Contribution, By Product, 2022 & 2030 (Value %)
FIG. 29 Global Oncology Molecular Diagnostics Market, by Instruments, Value, 2017-2030 (US$ Bn)
FIG. 30 Global Oncology Molecular Diagnostics Market, by Reagents, 2017-2030 (US$ Bn)
FIG. 31 Global Oncology Molecular Diagnostics Market, by Others, 2017-2030 (US$ Bn)
FIG. 32 Global Oncology Molecular Diagnostics Market Value Contribution, By Test Location, 2022 & 2030 (Value %)
FIG. 33 Global Oncology Molecular Diagnostics Market, by Clinics, Value, 2017-2030 (US$ Bn)
FIG. 34 Global Oncology Molecular Diagnostics Market, by Other Establishments, 2017-2030 (US$ Bn)
FIG. 35 Global Oncology Molecular Diagnostics Market, by Point of Care, 2017-2030 (US$ Bn)
FIG. 36 Global Oncology Molecular Diagnostics Market, by Other Test Locations, 2017-2030 (US$ Bn)
FIG. 37 Global Oncology Molecular Diagnostics Market Value Contribution, By Technology, 2022 & 2030 (Value %)
FIG. 38 Global Oncology Molecular Diagnostics Market, by PCR, Value, 2017-2030 (US$ Bn)
FIG. 39 Global Oncology Molecular Diagnostics Market, by Multiplex, 2017-2030 (US$ Bn)
FIG. 40 Global Oncology Molecular Diagnostics Market, by In Situ Hybridization, 2017-2030 (US$ Bn)
FIG. 41 Global Oncology Molecular Diagnostics Market, by Isothermal Nucleic Acid Amplification Technology (INAAT), 2017-2030 (US$ Bn)
FIG. 42 Global Oncology Molecular Diagnostics Market, by Chips and Microarrays, 2017-2030 (US$ Bn)
FIG. 43 Global Oncology Molecular Diagnostics Market, by Mass Spectrometry, 2017-2030 (US$ Bn)
FIG. 44 Global Oncology Molecular Diagnostics Market, by Sequencing, 2017-2030 (US$ Bn)
FIG. 45 Global Oncology Molecular Diagnostics Market, by Transcription Mediated Amplification, 2017-2030 (US$ Bn)
FIG. 46 Global Oncology Molecular Diagnostics Market, by Others, 2017-2030 (US$ Bn)
FIG. 47 Global Oncology Molecular Diagnostics Market Value Contribution, By End User, 2022 & 2030 (Value %)
FIG. 48 Global Oncology Molecular Diagnostics Market, by Hospitals, Value, 2017-2030 (US$ Bn)
FIG. 49 Global Oncology Molecular Diagnostics Market, by Diagnostic Centers, 2017-2030 (US$ Bn)
FIG. 50 North America Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 51 U.S. Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 52 Canada Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 53 Europe Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 54 Germany Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 55 France Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 56 U.K. Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 57 Italy Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 58 Spain Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 59 Rest of Europe Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 60 Asia Pacific Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 61 China Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 62 Japan Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 63 India Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 64 South Korea Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 65 South-East Asia Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 66 Rest of Asia Pacific Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 67 Latin America Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 68 Brazil Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 69 Mexico Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 70 Rest of Latin America Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 71 Middle East & Africa Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 72 GCC Countries Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 73 South Africa Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)
FIG. 74 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Oncology Molecular Diagnostics Market
TABLE 2 Global Oncology Molecular Diagnostics Market: Market Drivers Impact Analysis
TABLE 3 Global Oncology Molecular Diagnostics Market: Market Restraints Impact Analysis
TABLE 4 Global Oncology Molecular Diagnostics Market, by Competitive Benchmarking, 2022
TABLE 5 Global Oncology Molecular Diagnostics Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Oncology Molecular Diagnostics Market, by Key Strategies Analysis, 2022
TABLE 7 Global Oncology Molecular Diagnostics Market, by Breast Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Oncology Molecular Diagnostics Market, by Breast Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Oncology Molecular Diagnostics Market, by Prostate Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Oncology Molecular Diagnostics Market, by Prostate Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Oncology Molecular Diagnostics Market, by Colorectal Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Oncology Molecular Diagnostics Market, by Colorectal Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Oncology Molecular Diagnostics Market, by Cervical Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Oncology Molecular Diagnostics Market, by Cervical Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Oncology Molecular Diagnostics Market, by Liver Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Oncology Molecular Diagnostics Market, by Liver Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Oncology Molecular Diagnostics Market, by Lung Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Oncology Molecular Diagnostics Market, by Lung Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Oncology Molecular Diagnostics Market, by Blood Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 20 Global Oncology Molecular Diagnostics Market, by Blood Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 21 Global Oncology Molecular Diagnostics Market, by Kidney Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 22 Global Oncology Molecular Diagnostics Market, by Kidney Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 23 Global Oncology Molecular Diagnostics Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 24 Global Oncology Molecular Diagnostics Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 25 Global Oncology Molecular Diagnostics Market, by Instruments, By Region, 2017-2022 (US$ Bn)
TABLE 26 Global Oncology Molecular Diagnostics Market, by Instruments, By Region, 2023-2030 (US$ Bn)
TABLE 27 Global Oncology Molecular Diagnostics Market, by Reagents, By Region, 2017-2022 (US$ Bn)
TABLE 28 Global Oncology Molecular Diagnostics Market, by Reagents, By Region, 2023-2030 (US$ Bn)
TABLE 29 Global Oncology Molecular Diagnostics Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 30 Global Oncology Molecular Diagnostics Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 31 Global Oncology Molecular Diagnostics Market, by Clinics, By Region, 2017-2022 (US$ Bn)
TABLE 32 Global Oncology Molecular Diagnostics Market, by Clinics, By Region, 2023-2030 (US$ Bn)
TABLE 33 Global Oncology Molecular Diagnostics Market, by Other Establishments, By Region, 2017-2022 (US$ Bn)
TABLE 34 Global Oncology Molecular Diagnostics Market, by Other Establishments, By Region, 2023-2030 (US$ Bn)
TABLE 35 Global Oncology Molecular Diagnostics Market, by Point of Care, By Region, 2017-2022 (US$ Bn)
TABLE 36 Global Oncology Molecular Diagnostics Market, by Point of Care, By Region, 2023-2030 (US$ Bn)
TABLE 37 Global Oncology Molecular Diagnostics Market, by PCR, By Region, 2017-2022 (US$ Bn)
TABLE 38 Global Oncology Molecular Diagnostics Market, by PCR, By Region, 2023-2030 (US$ Bn)
TABLE 39 Global Oncology Molecular Diagnostics Market, by Multiplex, By Region, 2017-2022 (US$ Bn)
TABLE 40 Global Oncology Molecular Diagnostics Market, by Multiplex, By Region, 2023-2030 (US$ Bn)
TABLE 41 Global Oncology Molecular Diagnostics Market, by In Situ Hybridization, By Region, 2017-2022 (US$ Bn)
TABLE 42 Global Oncology Molecular Diagnostics Market, by In Situ Hybridization, By Region, 2023-2030 (US$ Bn)
TABLE 43 Global Oncology Molecular Diagnostics Market, by Isothermal Nucleic Acid Amplification Technology (INAAT), By Region, 2017-2022 (US$ Bn)
TABLE 44 Global Oncology Molecular Diagnostics Market, by Isothermal Nucleic Acid Amplification Technology (INAAT), By Region, 2023-2030 (US$ Bn)
TABLE 45 Global Oncology Molecular Diagnostics Market, by Chips and Microarrays, By Region, 2017-2022 (US$ Bn)
TABLE 46 Global Oncology Molecular Diagnostics Market, by Chips and Microarrays, By Region, 2023-2030 (US$ Bn)
TABLE 47 Global Oncology Molecular Diagnostics Market, by Mass Spectrometry, By Region, 2017-2022 (US$ Bn)
TABLE 48 Global Oncology Molecular Diagnostics Market, by Mass Spectrometry, By Region, 2023-2030 (US$ Bn)
TABLE 49 Global Oncology Molecular Diagnostics Market, by Sequencing, By Region, 2017-2022 (US$ Bn)
TABLE 50 Global Oncology Molecular Diagnostics Market, by Sequencing, By Region, 2023-2030 (US$ Bn)
TABLE 51 Global Oncology Molecular Diagnostics Market, by Transcription Mediated Amplification, By Region, 2017-2022 (US$ Bn)
TABLE 52 Global Oncology Molecular Diagnostics Market, by Transcription Mediated Amplification, By Region, 2023-2030 (US$ Bn)
TABLE 53 Global Oncology Molecular Diagnostics Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 54 Global Oncology Molecular Diagnostics Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 55 Global Oncology Molecular Diagnostics Market, by Hospitals, By Region, 2017-2022 (US$ Bn)
TABLE 56 Global Oncology Molecular Diagnostics Market, by Hospitals, By Region, 2023-2030 (US$ Bn)
TABLE 57 Global Oncology Molecular Diagnostics Market, by Diagnostic Centers, By Region, 2017-2022 (US$ Bn)
TABLE 58 Global Oncology Molecular Diagnostics Market, by Diagnostic Centers, By Region, 2023-2030 (US$ Bn)
TABLE 59 Global Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 60 Global Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 61 Global Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 62 Global Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 63 Global Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 64 Global Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 65 Global Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 66 Global Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 67 Global Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 68 Global Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 69 Global Oncology Molecular Diagnostics Market, by Region, 2017-2022 (US$ Bn)
TABLE 70 Global Oncology Molecular Diagnostics Market, by Region, 2023-2030 (US$ Bn)
TABLE 71 North America Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 72 North America Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 73 North America Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 74 North America Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 75 North America Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 76 North America Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 77 North America Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 78 North America Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 79 North America Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 80 North America Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 81 North America Oncology Molecular Diagnostics Market, by Country, 2017-2022 (US$ Bn)
TABLE 82 North America Oncology Molecular Diagnostics Market, by Country, 2023-2030 (US$ Bn)
TABLE 83 United States Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 84 United States Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 85 United States Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 86 United States Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 87 United States Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 88 United States Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 89 United States Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 90 United States Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 91 United States Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 92 United States Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 93 Canada Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 94 Canada Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 95 Canada Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 96 Canada Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 97 Canada Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 98 Canada Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 99 Canada Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 100 Canada Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 101 Canada Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 102 Canada Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 103 Mexico Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 104 Mexico Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 105 Mexico Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 106 Mexico Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 107 Mexico Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 108 Mexico Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 109 Mexico Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 110 Mexico Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 111 Mexico Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 112 Mexico Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 113 Europe Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 114 Europe Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 115 Europe Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 116 Europe Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 117 Europe Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 118 Europe Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 119 Europe Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 120 Europe Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 121 Europe Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 122 Europe Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 123 Europe Oncology Molecular Diagnostics Market, by Country, 2017-2022 (US$ Bn)
TABLE 124 Europe Oncology Molecular Diagnostics Market, by Country, 2023-2030 (US$ Bn)
TABLE 125 Germany Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 126 Germany Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 127 Germany Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 128 Germany Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 129 Germany Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 130 Germany Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 131 Germany Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 132 Germany Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 133 Germany Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 134 Germany Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 135 France Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 136 France Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 137 France Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 138 France Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 139 France Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 140 France Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 141 France Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 142 France Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 143 France Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 144 France Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 145 United Kingdom Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 146 United Kingdom Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 147 United Kingdom Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 148 United Kingdom Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 149 United Kingdom Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 150 United Kingdom Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 151 United Kingdom Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 152 United Kingdom Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 153 United Kingdom Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 154 United Kingdom Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 155 Italy Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 156 Italy Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 157 Italy Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 158 Italy Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 159 Italy Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 160 Italy Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 161 Italy Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 162 Italy Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 163 Italy Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 164 Italy Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 165 Spain Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 166 Spain Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 167 Spain Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 168 Spain Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 169 Spain Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 170 Spain Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 171 Spain Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 172 Spain Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 173 Spain Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 174 Spain Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 175 Rest of Europe Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 176 Rest of Europe Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 177 Rest of Europe Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 178 Rest of Europe Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 179 Rest of Europe Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 180 Rest of Europe Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 181 Rest of Europe Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 182 Rest of Europe Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 183 Rest of Europe Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 184 Rest of Europe Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 185 Asia Pacific Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 186 Asia Pacific Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 187 Asia Pacific Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 188 Asia Pacific Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 189 Asia Pacific Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 190 Asia Pacific Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 191 Asia Pacific Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 192 Asia Pacific Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 193 Asia Pacific Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 194 Asia Pacific Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 195 China Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 196 China Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 197 China Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 198 China Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 199 China Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 200 China Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 201 China Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 202 China Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 203 China Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 204 China Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 205 Japan Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 206 Japan Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 207 Japan Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 208 Japan Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 209 Japan Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 210 Japan Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 211 Japan Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 212 Japan Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 213 Japan Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 214 Japan Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 215 India Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 216 India Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 217 India Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 218 India Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 219 India Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 220 India Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 221 India Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 222 India Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 223 India Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 224 India Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 225 South Korea Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 226 South Korea Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 227 South Korea Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 228 South Korea Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 229 South Korea Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 230 South Korea Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 231 South Korea Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 232 South Korea Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 233 South Korea Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 234 South Korea Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 235 South-East Asia Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 236 South-East Asia Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 237 South-East Asia Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 238 South-East Asia Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 239 South-East Asia Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 240 South-East Asia Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 241 South-East Asia Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 242 South-East Asia Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 243 South-East Asia Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 244 South-East Asia Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 245 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 246 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 247 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 248 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 249 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 250 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 251 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 252 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 253 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 254 Rest of Asia Pacific Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 255 Latin America Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 256 Latin America Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 257 Latin America Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 258 Latin America Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 259 Latin America Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 260 Latin America Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 261 Latin America Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 262 Latin America Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 263 Latin America Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 264 Latin America Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 265 Brazil Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 266 Brazil Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 267 Brazil Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 268 Brazil Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 269 Brazil Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 270 Brazil Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 271 Brazil Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 272 Brazil Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 273 Brazil Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 274 Brazil Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 275 Argentina Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 276 Argentina Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 277 Argentina Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 278 Argentina Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 279 Argentina Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 280 Argentina Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 281 Argentina Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 282 Argentina Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 283 Argentina Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 284 Argentina Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 285 Rest of Latin America Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 286 Rest of Latin America Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 287 Rest of Latin America Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 288 Rest of Latin America Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 289 Rest of Latin America Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 290 Rest of Latin America Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 291 Rest of Latin America Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 292 Rest of Latin America Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 293 Rest of Latin America Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 294 Rest of Latin America Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 295 Middle East and Africa Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 296 Middle East and Africa Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 297 Middle East and Africa Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 298 Middle East and Africa Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 299 Middle East and Africa Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 300 Middle East and Africa Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 301 Middle East and Africa Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 302 Middle East and Africa Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 303 Middle East and Africa Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 304 Middle East and Africa Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 305 GCC Countries Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 306 GCC Countries Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 307 GCC Countries Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 308 GCC Countries Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 309 GCC Countries Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 310 GCC Countries Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 311 GCC Countries Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 312 GCC Countries Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 313 GCC Countries Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 314 GCC Countries Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 315 South Africa Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 316 South Africa Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 317 South Africa Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 318 South Africa Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 319 South Africa Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 320 South Africa Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 321 South Africa Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 322 South Africa Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 323 South Africa Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 324 South Africa Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)
TABLE 325 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by Type, 2017-2022 (US$ Bn)
TABLE 326 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by Type, 2023-2030 (US$ Bn)
TABLE 327 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by Product, 2017-2022 (US$ Bn)
TABLE 328 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by Product, 2023-2030 (US$ Bn)
TABLE 329 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by Test Location, 2017-2022 (US$ Bn)
TABLE 330 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by Test Location, 2023-2030 (US$ Bn)
TABLE 331 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by Technology, 2017-2022 (US$ Bn)
TABLE 332 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by Technology, 2023-2030 (US$ Bn)
TABLE 333 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by End User, 2017-2022 (US$ Bn)
TABLE 334 Rest of Middle East and Africa Oncology Molecular Diagnostics Market, by End User, 2023-2030 (US$ Bn)

Frequently asked questions

What is the current size of the global oncology molecular diagnostics market?

The global oncology molecular diagnostics market was valued at USD 4.5 Billion in 2022.

What is the expected growth rate of the oncology molecular diagnostics market between 2023 and 2030?

The oncology molecular diagnostics market is expected to grow at a CAGR of 15.5% between 2023 and 2030, reaching USD 12.3 Billion in 2030.

Which segment is leading the market share in terms of type?

Lung cancer is the leading segment by type, holding over 20% share in value in 2022.

Which product segment governs the demand for oncology molecular diagnostics worldwide?

Reagents govern the global demand for oncology molecular diagnostics, holding a massive share of over 30% in 2022.

Which test location segment governs the demand for oncology molecular diagnostics worldwide?

The clinics segment is expected to post the highest CAGR during the forecast period.

Which region is fueling the growth of the oncology molecular diagnostics industry?

North America is fueling the growth of the oncology molecular diagnostics industry, with an over one-third share in 2022.

Who are the major players in the global oncology molecular diagnostics market?

The top players include Abbott, Bayer AG, BD, Agilent Technologies, Inc, Danaher, Hologic, Inc., and QIAGEN.

What are the major market drivers of the oncology molecular diagnostics industry?

The major market drivers are the increasing prevalence of cancer, advancements in precision medicine, and growing emphasis on personalized medicine and targeted therapies.

What are the major market restraints of the oncology molecular diagnostics industry?

Major market restraints include high costs associated with molecular diagnostics, and complex regulatory landscape and the need for stringent validation and regulatory approvals.

What are the major market opportunities of the oncology molecular diagnostics industry?

Integration of artificial intelligence (AI) and machine learning (ML) algorithms, advancements in liquid biopsy technologies, and expansion of personalized medicine and targeted therapies.

Restorative Dentistry Market

Published:
Report ID: 36794

Prostate Cancer Diagnostics Market

Published:
Report ID: 36791

Ophthalmic Equipment Market

Published:
Report ID: 36788

Antioxidant Market

Published:
Report ID: 6987

Prostate Cancer Biopsy Market

Published:
Report ID: 36746

Molecular Targeted Diagnostics Market

Published:
Report ID: 36743

Drug Screening Market

Published:
Report ID: 36731

Cell Therapy Market

Published:
Report ID: 36722

Cannabidiol Market

Published:
Report ID: 36719

Blood Collection Devices Market

Published:
Report ID: 36716

Pimple Patches Market

Published:
Report ID: 36706

Personalized Nutrition Market

Published:
Report ID: 36703

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN